Astria Therapeutics (ATXS) Cash & Equivalents: 2017-2019
Historic Cash & Equivalents for Astria Therapeutics (ATXS) over the last 3 years, with Sep 2019 value amounting to $17.8 million.
- Astria Therapeutics' Cash & Equivalents fell 10.62% to $17.8 million in Q3 2019 from the same period last year, while for Sep 2019 it was $17.8 million, marking a year-over-year decrease of 10.62%. This contributed to the annual value of $15.3 million for FY2018, which is 6.57% down from last year.
- Latest data reveals that Astria Therapeutics reported Cash & Equivalents of $17.8 million as of Q3 2019, which was up 84.76% from $9.6 million recorded in Q2 2019.
- Astria Therapeutics' 5-year Cash & Equivalents high stood at $49.9 million for Q2 2018, and its period low was $9.6 million during Q2 2019.
- In the last 3 years, Astria Therapeutics' Cash & Equivalents had a median value of $17.8 million in 2019 and averaged $21.9 million.
- Per our database at Business Quant, Astria Therapeutics' Cash & Equivalents soared by 70.01% in 2018 and then crashed by 80.74% in 2019.
- Over the past 3 years, Astria Therapeutics' Cash & Equivalents (Quarterly) stood at $16.4 million in 2017, then declined by 6.57% to $15.3 million in 2018, then declined by 10.62% to $17.8 million in 2019.
- Its last three reported values are $17.8 million in Q3 2019, $9.6 million for Q2 2019, and $11.7 million during Q1 2019.